NNE1

NNE1
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Class B;
Identifiers
	IUPAC name N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide;
CAS Number	1338925-11-3;
PubChem CID	54752945;
ChemSpider	26613275;
UNII	7FVT9P642K;
CompTox Dashboard (EPA)	DTXSID50716467 ;
Chemical and physical data
Formula	C24H24N2O
Molar mass	356.469 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCn1cc(c2c1cccc2)C(=O)Nc1cccc2c1cccc2;
	InChI InChI=1S/C24H24N2O/c1-2-3-8-16-26-17-21(20-13-6-7-15-23(20)26)24(27)25-22-14-9-11-18-10-4-5-12-19(18)22/h4-7,9-15,17H,2-3,8,16H2,1H3,(H,25,27); Key:GWCQNKRMTGVYIZ-UHFFFAOYSA-N;

NNE1 (also known as NNEI, MN-24 and AM-6527) is an indole-based synthetic cannabinoid, representing a molecular hybrid of APICA and JWH-018^[1] that is an agonist for the cannabinoid receptors, with K_i values of 60.09 nM at CB₁ and 45.298 nM at CB₂ and EC₅₀ values of 9.481 nM at CB₁ and 1.008 nM at CB₂.^[2] It was designed by Jos Lange at Abbott in 2010 to serve as an in vivo active pharmacological tool and has a CB₁ receptor pEC₅₀ of 8.9 with around 80x selectivity over the related CB₂ receptor.^[3] It is suspected that metabolic hydrolysis of the amide group of NNE1 may release 1-naphthylamine, a known carcinogen, given the known metabolic liberation (and presence as an impurity) of amantadine in the related compound APINACA, and NNE1 was banned in New Zealand in 2012 as a temporary class drug to stop it being used as an ingredient in then-legal synthetic cannabis products.^[4] NNE1 was subsequently found to be responsible for the death of a man in Japan in 2014.^[5]

Quick facts Legal status, Identifiers ...

[1]

[2]

[3]

[4]

[5]

NNE1

See also

References

Wikiwand - on